Enodia Therapeutics raised €20.7M to advance AI-powered small molecules targeting SEC61 for selective protein degradation. Find out what this could change.
Samsung Bioepis secures Japan approval for its ustekinumab biosimilar with Nipro, marking a key step in Asia's biosimilar adoption. Find out what this means.
PRISM BioLab and Talus Bio aim to drug the undruggable with AI–PPI chemistry. Find out how this platform could transform transcription factor drug discovery.
AstraZeneca has received European Commission approval for a new subcutaneous formulation of Saphnelo (anifrolumab), allowing adult patients with systemic lupus erythematosus (SLE) to self-administer the drug via a once-weekly pre-filled pen. The regulatory decision follows a positive opinion from the Committee for Medicinal Products for Human Use and is supported by data from the Phase
When Amgen (NASDAQ: AMGN) announced that the U.S. Food and Drug Administration had approved UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis (gMG), the industry’s attention snapped not just to the therapy’s mechanism but to its twice-yearly maintenance schedule. For patients, this marks a seismic shift away from the exhausting cycle of daily oral immunosuppressants